JP2008510716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008510716A5 JP2008510716A5 JP2007528019A JP2007528019A JP2008510716A5 JP 2008510716 A5 JP2008510716 A5 JP 2008510716A5 JP 2007528019 A JP2007528019 A JP 2007528019A JP 2007528019 A JP2007528019 A JP 2007528019A JP 2008510716 A5 JP2008510716 A5 JP 2008510716A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antagonist
- lyophilized
- reconstituted
- sucrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60213704P | 2004-08-17 | 2004-08-17 | |
| US60/602,137 | 2004-08-17 | ||
| PCT/US2005/029428 WO2006023665A2 (en) | 2004-08-17 | 2005-08-17 | Il-1 antagonist formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012013973A Division JP2012121894A (ja) | 2004-08-17 | 2012-01-26 | Ｉｌ−１アンタゴニスト製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008510716A JP2008510716A (ja) | 2008-04-10 |
| JP2008510716A5 true JP2008510716A5 (enExample) | 2008-05-22 |
| JP4948410B2 JP4948410B2 (ja) | 2012-06-06 |
Family
ID=35968186
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007528019A Expired - Fee Related JP4948410B2 (ja) | 2004-08-17 | 2005-08-17 | Ｉｌ−１アンタゴニスト製剤 |
| JP2012013973A Pending JP2012121894A (ja) | 2004-08-17 | 2012-01-26 | Ｉｌ−１アンタゴニスト製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012013973A Pending JP2012121894A (ja) | 2004-08-17 | 2012-01-26 | Ｉｌ−１アンタゴニスト製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7365165B2 (enExample) |
| EP (2) | EP1778723B1 (enExample) |
| JP (2) | JP4948410B2 (enExample) |
| CN (1) | CN101014617B (enExample) |
| AU (1) | AU2005277357B2 (enExample) |
| BR (1) | BRPI0514411B8 (enExample) |
| CA (1) | CA2576519C (enExample) |
| DK (1) | DK1778723T3 (enExample) |
| ES (1) | ES2395035T3 (enExample) |
| PL (1) | PL1778723T3 (enExample) |
| PT (1) | PT1778723E (enExample) |
| SI (1) | SI1778723T1 (enExample) |
| WO (1) | WO2006023665A2 (enExample) |
| ZA (1) | ZA200701529B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0413276B8 (pt) | 2003-08-05 | 2021-05-25 | Novo Nordisk As | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica |
| PL1969004T3 (pl) | 2005-12-28 | 2012-01-31 | Novo Nordisk As | Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji |
| SI2944306T1 (sl) | 2006-06-16 | 2021-04-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
| EP2150537A4 (en) * | 2007-06-01 | 2010-09-22 | Acologix Inc | STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE |
| WO2008152106A1 (en) | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| US9492375B2 (en) * | 2008-07-23 | 2016-11-15 | Warsaw Orthopedic, Inc. | Foam carrier for bone grafting |
| WO2010049488A1 (en) | 2008-10-30 | 2010-05-06 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| DK2598526T3 (en) | 2010-07-29 | 2018-11-19 | Eleven Biotherapeutics Inc | CHEMICAL IL-1 RECEPTOR TYPE-I AGONISTS AND ANTAGONISTS |
| RU2013123515A (ru) | 2010-10-27 | 2014-12-10 | Ново Нордиск А/С | Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами |
| ES2810003T3 (es) | 2011-11-18 | 2021-03-08 | Regeneron Pharma | Micropartícula que contiene proteína terapéutica recubierta con polímero biodegradable para uso médico |
| AU2012330497B2 (en) * | 2012-04-04 | 2016-08-04 | Polaris Group | Methods of treating with arginine deiminase |
| WO2014035361A1 (en) * | 2012-08-26 | 2014-03-06 | R-PHARM, CJSC (Closed Joint Stock Company) | IL-1β INHIBITOR COMPOSITION AND USE THEREOF |
| CA2903706C (en) | 2013-03-13 | 2024-01-23 | Eleven Biotherapeutics, Inc. | Chimeric cytokine formulations for ocular delivery |
| WO2014177623A1 (en) | 2013-04-30 | 2014-11-06 | Novo Nordisk A/S | Novel administration regime |
| JP7170329B2 (ja) | 2016-09-16 | 2022-11-14 | ロイコケア・アクチェンゲゼルシャフト | 処理中の生物医薬製品の安定化のための新規な方法 |
| WO2018050872A1 (en) | 2016-09-16 | 2018-03-22 | Leukocare Ag | A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
| WO2018085551A2 (en) | 2016-11-02 | 2018-05-11 | Polaris Group | Formulations of pegylated arginine deiminase |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| JP7518149B2 (ja) | 2019-07-12 | 2024-07-17 | ノヴォ ノルディスク アー／エス | 高濃度インスリン製剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993000807A1 (en) * | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
| JP3822383B2 (ja) * | 1993-12-17 | 2006-09-20 | 持田製薬株式会社 | 可溶性トロンボモジュリン含有組成物 |
| ATE216590T1 (de) * | 1995-02-06 | 2002-05-15 | Genetics Inst | Arzneimittelformulierungen für il-12 |
| US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| JP4172842B2 (ja) * | 1997-05-02 | 2008-10-29 | 生化学工業株式会社 | コンドロイチナーゼ組成物 |
| US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| DE10204792A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Immuncytokine |
| CA2512680A1 (en) * | 2003-01-08 | 2004-07-29 | Chiron Corporation | Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
-
2005
- 2005-08-17 PL PL05789252T patent/PL1778723T3/pl unknown
- 2005-08-17 BR BRPI0514411A patent/BRPI0514411B8/pt not_active IP Right Cessation
- 2005-08-17 WO PCT/US2005/029428 patent/WO2006023665A2/en not_active Ceased
- 2005-08-17 PT PT57892523T patent/PT1778723E/pt unknown
- 2005-08-17 CN CN2005800281894A patent/CN101014617B/zh not_active Expired - Lifetime
- 2005-08-17 AU AU2005277357A patent/AU2005277357B2/en not_active Ceased
- 2005-08-17 ES ES05789252T patent/ES2395035T3/es not_active Expired - Lifetime
- 2005-08-17 EP EP05789252A patent/EP1778723B1/en not_active Expired - Lifetime
- 2005-08-17 US US11/205,935 patent/US7365165B2/en active Active
- 2005-08-17 EP EP10010576A patent/EP2311871A3/en not_active Withdrawn
- 2005-08-17 CA CA2576519A patent/CA2576519C/en not_active Expired - Fee Related
- 2005-08-17 SI SI200531654T patent/SI1778723T1/sl unknown
- 2005-08-17 JP JP2007528019A patent/JP4948410B2/ja not_active Expired - Fee Related
- 2005-08-17 DK DK05789252.3T patent/DK1778723T3/da active
-
2007
- 2007-02-21 ZA ZA2007/01529A patent/ZA200701529B/en unknown
-
2012
- 2012-01-26 JP JP2012013973A patent/JP2012121894A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008510716A5 (enExample) | ||
| JP2013079270A5 (enExample) | ||
| JP2009540001A5 (enExample) | ||
| RU2011127913A (ru) | Составы, содержащие антитела | |
| Kawasaki et al. | Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects | |
| US12186384B2 (en) | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens | |
| CA2187083C (fr) | Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation | |
| JP2012121894A (ja) | Ｉｌ−１アンタゴニスト製剤 | |
| CN102202688B (zh) | 稳定、干燥的轮状病毒疫苗、其组合物和制备其的方法 | |
| WO2007147001A3 (en) | Lyophilized formulations of anti-egfr antibodies | |
| WO2008150479A3 (en) | High temperature stable peptide formulation | |
| JP2013511557A5 (enExample) | ||
| RU2012125254A (ru) | Составы антитела | |
| JP2012531442A5 (enExample) | ||
| IL310367A (en) | A stable protein at room temperature that has been lyophilized | |
| CA2272245A1 (en) | Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies | |
| JP2015231997A5 (enExample) | ||
| RU2008148830A (ru) | Препарат вакцины на основе конъюгата никотин-носитель | |
| JP2011530524A5 (enExample) | ||
| JP2016520075A5 (enExample) | ||
| Hirschberg et al. | Bioneedles as alternative delivery system for hepatitis B vaccine | |
| HRP20140886T1 (hr) | MUTANTI CyaA POLIPEPTIDI I POLIPEPTIDNI DERIVATI PRIKLADNI ZA DOPREMANJE IMUNOGENIÄŚNIH MOLEKULA U STANICU | |
| JP2003532636A5 (enExample) | ||
| JP2013510158A5 (enExample) | ||
| HRP20240176T1 (hr) | Formulacije |